Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Ian Haydock

Tokyo, Japan
Ian is head of pharma news content for the Asia-Pacific area and has been covering the region for more than 20 years as an editor for Scrip and more recently as managing editor of PharmAsia News. He has a long background in Asia, having grown up in Hong Kong, and a particular interest in regional regulatory harmonization and trade initiatives and the development of the Japanese pharma sector. Ian lives in Tokyo with his wife and two sons.
Advertisement
Set Alert for Articles By Ian Haydock

Latest From Ian Haydock

Improving Profitability A Key Mid-Term Focus For Takeda

CEO Christophe Weber remains resolutely upbeat on the progress of Takeda's strategic transformation plan, the dividends of which he said are apparent in the leading Japanese pharma firm's fiscal year performance.

Commercial Companies

Deal Watch: Seattle Genetics' Controversial Collaboration With Immunomedics Topples

A licensing deal between the two cancer-focused biotechs falls apart amidst investor unrest at Immunomedics. Novartis opts to license Conatus' Phase II NASH candidate and picks up a CAR-T candidate from Celyad, while Shire adds to its dry eye franchise in deal with Parion.

Deals M & A

China Leads Strong AstraZeneca Emerging Markets Charge In Q1

Despite a fall in overall revenue, emerging markets continued to perform strongly for AstraZeneca in the first quarter, becoming the UK group's single largest sales region globally, driven mainly by China.

China Emerging Markets

Brigatinib Approval Validates Ariad Buy, But Can Takeda Carve A Position?

The US approval of the targeted kinase inhibitor brigatinib seems to provide early validation of Takeda's recent acquisition of Ariad, but can the molecule carve its own niche amid intensifying same-class competition?

Commercial Strategy

Novartis Slapped With New $49m Fine For Korea ‘Rebates’

Novartis's South Korean subsidiary has been hit with a new fine of around $49m and reimbursement suspensions for a number of its drugs under a new ministerial action related to illegal "rebate" payments made to prescribers.

South Korea Legal Issues

ASLAN Firms Up IPO Plans As Lead Asset Progresses

Amid recent progress for its lead molecule, ASLAN has firmed up plans for the timing of its initial public offering, which is now expected to take place in Taiwan mid May with the newly listed shares set to begin trading in early June.

ImmunoOncology Financing
See All
Advertisement
UsernamePublicRestriction

Register